Media Center

 

Third Rock News & Events

January 26, 2017 - Third Rock Ventures Names Sarah Larson as Partner
» Read More

October 31, 2016 - Third Rock Ventures Raises $616 Million Fund IV
» Read More

September 24, 2016 - Third Rock Ventures’ Venture Partner Phil Reilly to receive the Henri Termeer Lifetime Achievement Award at the 5th Annual Tribute to Champions of Hope
» Read More

May 23, 2016 - Third Rock Ventures’ Venture Partner Phil Reilly to Speak at MassBio Event to Discuss his New Book “Orphan: The Quest to Save Children with Rare Disease”
» Read More

April 25, 2016 - Third Rock Ventures' Partner, Robert Tepper, to Moderate Panel at the World Medical Innovation Forum
» Read More

April 6, 2016 - Third Rock Ventures' Partner, Cary Pfeffer, to Present at Xconomy's EXOME: What's Hot in Boston Biotech
» Read More

Portfolio News

Cedilla Therapeutics
April 24, 2018 - Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics
» Press Release | Company News

bluebird bio
April 18, 2018 - bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
» Press Release | Company News

Foundation Medicine
April 17, 2018 - Foundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference Call
» Press Release | Company News

SAGE Therapeutics
April 17, 2018 - Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
» Press Release | Company News

bluebird bio
April 16, 2018 - bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
» Press Release | Company News

Taris Biomedical
April 16, 2018 - TARIS® Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine
» Press Release | Company News

Blueprint Medicines
April 15, 2018 - Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
» Press Release | Company News

Blueprint Medicines
April 15, 2018 - Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
» Press Release | Company News

Eleven Biotherapeutics
April 12, 2018 - New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
» Press Release | Company News

Jounce Therapeutics
April 12, 2018 - Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
» Press Release | Company News

News Archives